Related Experiment Video

Updated: Oct 1, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside

Maria João de Sousa1,2, Lorenzo Gervaso2,3, Monica Isabel Meneses-Medina2,4

  • 1Medical Oncology Department, Instituto Português de Oncologia de Coimbra Francisco Gentil EPE, IPO Coimbra, Coimbra, Portugal.

Current Oncology Reports
|March 9, 2022
PubMed
Abstract

Insights

Cyclin-dependent kinase (CDK) 4/6 inhibitors show promise in neuroendocrine neoplasms (NENs). While antitumor effects are still under investigation, trilaciclib demonstrates significant myeloprotective benefits in small cell lung cancer (SCLC).

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinases (CDKs) are critical regulators of cell division.
  • CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib have shown antitumor activity.
  • Trilaciclib, a CDK4/6 inhibitor, exhibits myeloprotective effects in chemotherapy.

Purpose of the Study:

  • To review current evidence on CDK4/6 inhibitors in neuroendocrine neoplasms (NENs).

Main Methods:

  • Review of preclinical data and clinical trials involving CDK4/6 inhibitors in NENs.
  • Examination of trilaciclib's role in mitigating chemotherapy-induced myelosuppression.

Main Results:

  • Preclinical studies suggest CDK4/6 inhibitors have antitumor potential in neuroendocrine tumors (NETs).
  • Limited clinical trials in NETs have not yet demonstrated significant improvements in progression-free survival or objective response.
  • Trilaciclib effectively reduces chemotherapy-induced myelosuppression in small cell lung cancer (SCLC).

Conclusions:

  • CDK4/6 inhibitors remain investigational for antitumor therapy in NENs.
  • Trilaciclib is approved for routine use in extensive-stage SCLC to manage myelotoxicity.
Keywords:
Abemaciclib; trilaciclibNeuroendocrine tumors; CDK4/6 inhibitorsPalbociclibRibociclib

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K
Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

1.4K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
276
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K